Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol

Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol

Chad Moretz1, Lindsay GS Bengtson2, Lucie Sharpsten2, Eleena Koep2, Lisa Le2, Junliang Tong2, Richard H Stanford1, Beth Hahn1, Riju Ray1 1Glaxo Smith Kline, Research Triangle Park, Durham, NC, USA; 2Optum, Eden Prairie, MN, USACorrespondence: Chad MoretzGlaxoSmithKline, Research Triangle Park, 5 Moo...

Full description

Bibliographic Details
Main Authors:	Moretz C, Bengtson LGS, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-09-01
Series:	International Journal of COPD
Subjects:	COPD long-acting β2-agonists long-acting muscarinic antagonists adherence rescue medication real world
Online Access:	https://www.dovepress.com/evaluation-of-rescue-medication-use-and-medication-adherence-receiving-peer-reviewed-article-COPD

Similar Items

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study
by: Requena G, et al.
Published: (2021-03-01)

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
by: Albertson TE, et al.
Published: (2019-06-01)

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
by: Requena G, et al.
Published: (2023-07-01)

Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease
by: Takahashi K, et al.
Published: (2021-12-01)

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD
by: Feldman G, et al.
Published: (2016-04-01)

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
by: Dhvani Shah, et al.
Published: (2018-05-01)

Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis
by: Yogesh Suresh Punekar, et al.
Published: (2017-05-01)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
by: Plate T, et al.
Published: (2020-06-01)

Barriers to achieving asthma control in adults: evidence for the role of tiotropium in current management strategies
by: Jenkins C
Published: (2019-03-01)

Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
by: Puggioni F, et al.
Published: (2020-11-01)

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
by: Sang Haak Lee, et al.
Published: (2021-04-01)

Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study
by: Jutta Beier, et al.
Published: (2013-08-01)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
by: Beier J, et al.
Published: (2017-06-01)

Differential Response to 12 Weeks of Once-Daily Tiotropium/Olodaterol Fixed Dose Combination in Patients with COPD: A Multidimensional Response Profiling in the TORRACTO Study
by: Posthuma R, et al.
Published: (2023-06-01)

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
by: Moretz C, et al.
Published: (2019-08-01)

Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation
by: S. К. Zyryanov, et al.
Published: (2022-07-01)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
by: Czira A, et al.
Published: (2023-04-01)

Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA versus ICS/LABA in COPD Management: Findings from Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study
by: Ye Jin Lee, et al.
Published: (2021-12-01)

COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy
by: Moretz C, et al.
Published: (2020-09-01)

A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids
by: Edward Kerwin, et al.
Published: (2020-06-01)

Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History
by: Sethi S, et al.
Published: (2023-04-01)

Long-acting Bronchodilators in COPD Management: One or Two?
by: Konstantinos Kostikas, et al.
Published: (2023-01-01)

The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study
by: Christianne M. Blais, et al.
Published: (2017-08-01)

Combinations of long acting β2 agonists to tiotropium: A randomized, double-blind, placebo-controlled, active-drug controlled, parallel design academic clinical trial in moderate COPD male patients
by: Mohammed Imran, et al.
Published: (2015-01-01)

Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis
by: Michele Baroffio, et al.
Published: (2017-07-01)

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
by: Antonio Anzueto, et al.
Published: (2020-07-01)

Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population
by: Bogart M, et al.
Published: (2019-02-01)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
by: Kang J, et al.
Published: (2017-12-01)

Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials
by: Li CX, et al.
Published: (2019-04-01)

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
by: Tariq SM, et al.
Published: (2017-06-01)

Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
by: Kim HC, et al.
Published: (2019-03-01)

Effect of Tiotropium Soft Mist Inhalers on Dynamic Changes in Lung Mechanics of Patients with Chronic Obstructive Pulmonary Disease Receiving Mechanical Ventilation: A Prospective Pilot Study
by: Pin-Kuei Fu, et al.
Published: (2020-12-01)

Normalisation of airflow limitation in asthma: Post‐hoc analyses of TRIMARAN and TRIGGER
by: Alberto Papi, et al.
Published: (2022-04-01)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
by: Dave Singh, et al.
Published: (2020-10-01)

Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: Results from an Observational Cross-Sectional Physician and Patient Survey
by: Mannino D, et al.
Published: (2022-04-01)

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
by: James F. Donohue, et al.
Published: (2020-05-01)

Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary Disease
by: Collier DJ, et al.
Published: (2020-06-01)

Striving for optimal bronchodilation: focus on olodaterol
by: Incorvaia C, et al.
Published: (2016-03-01)